Non-Insulin Therapies for Diabetes Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026


Posted October 16, 2018 by coherent3

Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces.

 
Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces. Non-insulin-based medication works with different mechanism of action to reduce blood glucose level and maintain it for optimum glycemic control. For instance, some agents increase the insulin release from pancreatic cells (Sulfonylureas), some agents increase glucose uptake by periphery and reduces hepatic glucose output (Biguanides), some agents slow down digestion of starch in small intestine (alpha glucosidase inhibitors), and some medication reduces post meal sugar by blocking certain enzymes (Incretin mimetics)

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2042

Non-Insulin Therapies for Diabetes Market Dynamics
Increasing global incidence and prevalence of diabetes is expected to fuel growth of the non-insulin therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide prevalence of diabetic patients was around 425 million, of which around 400 million patients were suffering from type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S.

Market Key Players:-
AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.
Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/2042

Non-insulin Therapies for Diabetes Market: Taxonomy
On the basis of drug class, the global non-insulin therapies for diabetes market is segmented into:
• Biguanides
• Sulfonylureas
• Thiazolidinedione’s
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• GLP-1 Analogs
• Sodium-glucose co-transporter-2 (SGLT2) inhibitors 
On the basis of route of administration, the global non-insulin therapies for diabetes market is segmented into:
• Oral
• Intramuscular
On the basis of distribution channel, the global non-insulin therapies for diabetes market is segmented into:
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
On the basis of region, the global non-insulin therapies for diabetes market is segmented into:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By coherent
Country Bahamas
Categories Fitness , Health
Tags Non-Insulin Therapies for Diabetes Market Share, , Diabetes Market Growth , Non-Insulin Therapies for Diabetes Market Analysis,
Last Updated October 16, 2018